Safety and Efficacy of Lorbrena

Pfizer1,290 enrolled

Overview

To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug 1. Factors affecting the onset of central nervous system disorder 2. Effect of Lorbrena in combination with CYP3A inducers on the onset of hepatic dysfunction

Study Type

OBSERVATIONAL

Enrollment

1,290

Conditions

Non-small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 0 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All administered patients Exclusion Criteria: * Nothing

Locations (1)

3-22-7, Yoyogi, Shibuya-ku

Tokyo, Japan

Outcomes

Primary Outcomes

Incidence of adverse drug reactions of central nervous system disorder and hepatic dysfunction

Time frame: 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.